Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05517330 | Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma | PHASE2 | COMPLETED | 23 | — | — | Sep 19, 2022 | Jul 31, 2024 | Jul 31, 2025 | 1 | China |
Major Pathologic Response (MPR) was defined as fewer than 10% viable tumor cells.
| Arm | Type | Description |
|---|---|---|
| Treatment Cohort | EXPERIMENTAL | * Tislelizumab administration on days 1 and 22, and afatinib continuous administration from days 1 to 42 * Standard of care surgery |
| Name | Type | Description |
|---|---|---|
| Tislelizumab | BIOLOGICAL | 200mg IV Q3W |
| Afatinib | DRUG | 30mg PO QD |
Inclusion Criteria: 1. Age 18 years or above. 2. Patients with pathologically confirmed HNSCC (except for nasopharyngeal carcinoma) and meet the following conditions: * were newly diagnosed and without distant metastasis; * were deemed surgically resectable evaluated by a head and neck surge...